BMC Pulm Med. 2026 Jul 11. doi: 10.1186/s12890-026-04439-0. Online ahead of print.
ABSTRACT
BACKGROUND: Neonatal acute respiratory distress syndrome (NARDS) can cause respiratory failure in newborns and even pose a threat to their lives, causing a heavy financial burden on families.
AIM: This study aims to explore the potential role of miR-155 as a diagnostic marker and prognostic predictor for NARDS.
METHODS: This study included 100 non-NARDS newborns and 100 NARDS newborns. The plasma miR-155 expression was measured by RT-qPCR. The ROC curve was used to analyze the diagnostic efficacy of miR-155 alone and the combined diagnostic efficacy of PT, APTT, FIB, and CRP. The correlation between clinical indicators and miR-155 expression was analyzed by the chi-square test. The general clinical information of NARDS neonates with different severity degrees and prognosis was compared. Multivariate logistic regression was used to identify the risk factors for NARDS.
RESULTS: The plasma miR-155 level was elevated in NARDS newborns. miR-155 may serve as a promising biomarker in the diagnosis of NARDS. The value of the multi-factor combined diagnosis was significantly improved. 1-minute Apgar score, PT, APTT, and CRP level were statistically related to the miR-155 expression. Abnormal FIB level and the miR-155 expression were independent risk factors for NARDS. The more severe NARDS newborns have poorer coagulation function, stronger inflammatory response, and higher miR-155 level. A higher level of miR-155 was observed in NARDS newborns with a poorer prognosis.
CONCLUSION: The plasma miR-155 level is upregulated in NARDS, and miR-155 may be a potential diagnostic marker for NARDS. NARDS newborns with miR-155 high expression have a poor prognosis.
PMID:42436500 | DOI:10.1186/s12890-026-04439-0
